By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – http://careers.regeneron.com


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotech 





Company News
Regeneron (REGN)'s George Yancopoulos Becomes Pharma's First Billionaire R&D Chief 7/29/2015 6:52:08 AM
Sanofi (SNY) and Regeneron (REGN) Ink $2.2 Billion Immuno-Oncology, PD-1 Inhibitor Deal 7/28/2015 5:48:51 AM
Sanofi (SNY), Regeneron (REGN)’s $15,000-a-Year Heart Drug May Trigger New Cost Concerns 7/27/2015 7:21:29 AM
FDA Approves Cholesterol Drug Praluent From Regeneron (REGN), Sanofi (SNY) 7/24/2015 2:07:33 PM
Regeneron (REGN), Sanofi (SNY)'s Big New Cholesterol Drug Praluent Wins European Green Light 7/24/2015 6:08:02 AM
Amgen (AMGN) Beats Sanofi (SNY)/Regeneron (REGN) to European Market for Cholesterol Drug, but Race is Still on for U.S. Market 7/21/2015 6:07:39 AM
Regeneron (REGN) And Sanofi (SAN.PA) Announce Phase III Results Showing LDL-C Reductions Of More Than 60 Percent In Japanese Patients Treated With Praluent(Alirocumab) Injection 7/9/2015 9:24:23 AM
Regeneron (REGN), Sanofi (SAN.PA)'s Praluent Delivers in Late Stage Trial 7/9/2015 6:21:46 AM
Regeneron (REGN) To Report Second Quarter 2015 Financial And Operating Results And Host Conference Call And Webcast On August 4, 2015 7/8/2015 10:06:03 AM
Regeneron (REGN) Rapid Response Platform For Emerging Infectious Diseases Described In Proceedings Of The National Academy of Sciences Publication 6/30/2015 7:48:37 AM
12345678910...
//-->